Generate Biomedicines has completed its IPO, raising an impressive $400 million that makes it the largest listing for a biotech on the Nasdaq so far this year. Incubated by investment group Flagship ...

Other choices are more perplexing. As though to ensure everyone is following the plot, Middleton has incorporated spoken text ...

Humans may be primarily visual creatures, but for decades, the sharpest horror filmmakers have understood that if you want to really scare your audience, you can’t just focus on what they see. You ...

Generate:Biomedicines has hit the public markets as the world begins to question the usefulness of AI technology. CEO Mike Nally says biology is the key to unlocking the technology’s full potential.

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Generate Biomedicines Inc. shares slumped 21% in the company’s trading debut after it raised $400 million in an initial public offering. Shares of the Somerville, Massachusetts-based drug developer ...